INVESTIGATION OF ANTI-CANCER POTENTIAL OF PLANT EXTRACT USING MURINE CANCER CELL LINE XENOGRAFT MODEL IN EXPERIMENTAL ANIMALS

                                                              STUDY PROTOCOL

INVESTIGATION OF ANTI-CANCER POTENTIAL OF PLANT EXTRACT USING MURINE CANCER CELL LINE XENOGRAFT MODEL IN EXPERIMENTAL ANIMALS.

 

1.0  TEST SYSTEM DETAILS:STUDY

Species                  : Mus musculus (Mouse)

Strain                     : C57bl/6 or Balb/c or Swiss albino

Age                       : 6-10 weeks

Body Wight          : 20-25 g

Sex                        : Male or Female

No. of animals       : 8 /Group

Total animal          : 48+12 Extra= 60

2.0   ALLOCATION OF GROUPS:

 

Groups	Treatment	Dose; ROA	No. of Animals
G1	Normal Control	Normal saline or 0.25% Na-CMC	8
G2	Reference Drug- Paclitaxel	10 mpk; i.p.	8
G3	Plant Extract-1	X mpk; p.o.	8
G4	Plant Extract-1	XX mpk; p.o.	8
G5	Plant Extract-2	Y mpk; p.o.	8
G6	Plant Extract-2	YY mpk; p.o.	8

 

Extra 12 animals will be taken considering the tumor take-up rate

Cell lines: B16-F10, HEPG2, L6, 3T3-L1, RAW264.7

 

3.0  METHOD:

·         Animals shall be procured from the CPCSEA authorized vendor.

·         Animals shall be quarantined for 1 week as per the in house SOP.

·         Healthy animals will be selected, randomized based on body weight and divided into 6 different groups consisting of 8 animals each.

·         Cell Culture:

·         Murine cancer cell line will be procured from American Type Culture Collection USA, NCCS Pune or from authorized vendors cultured from suitable media supplemented with FBS or FCS or as applicable.

·         The cells were incubated in a humidified 5% CO2 atmosphere at 37°C and harvested during the logarithmic growth phase.

·         The 1-20X10⁶/100µL cells in phosphate-buffered saline (PBS) or serum free media will be and injected surgically into the cell line specific organ.

·         Drug treatment will be given as follows:

·         Group G1 animals will be treated as normal control and treated with normal saline or Na- CMC.

·         Animals of group G2 will be treated intraperitoneally with paclitaxel weekly twice at the dose of 10mpk.

·         Group G3, G4, G5, and G6 animals will be treated with plant extract(s)/herbal formulation at different dose levels.

·         Tumor progression was followed by in vivo optical imaging system.

·         Animal’s blood will be withdrawn via retro-orbital plexus and serum will be stored until analyzed.

·         All the animals will be humanely sacrificed at the end of the experiment.

 

4.0   ENDPOINT PARAMETER(S):

·         Clinical Observation

·         Body weight change

·         Tumor images

·         Tumor metastasis

 

5.0   REFERENCE(S):

5.1  Selene Nunez-Cruz, Denise C. Connolly, and Nathalie Scholler. An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses. J Vis Exp. 2010; (45): 2146.

                                                                       END OF THE DOCUMENT

1. EVALUATION OF ANTI-CANCER POTENTIAL OF PLANT EXTRACT(S)/HERBAL FORMULATION(S) USING HUMAN CANCER CELL LINE XENOGRAFT MODEL IN IMMUNOCOMPROMISED ANIMALS

2. EVALUATION OF ANTI-CANCER POTENTIAL OF PLANT EXTRACT(S)/HERBAL FORMULATION(S) USING HUMAN CANCER CELL LINE ORTHOTOPIC MODEL IN IMMUNOCOMPROMISED ANIMALS

SHARE

Owner

Hi. I’m Writer of Researchsop.com. ’ ’ Please share these SOPs to all concern pharma people for their development. I like to fullfill the need of curious people. These things inspire me to make things looks better.

• 
• 
• 
• 
•